This page is provided for research and educational purposes only and does not provide medical advice, diagnosis, treatment recommendations, dosing instructions, or instructions for human use. Research findings should be interpreted within the population, model, formulation, route, outcomes, and study design reported by each cited source.
SLU-PP-332 (5 mg Vial)
This information is for research and educational use only.
Quick Reference
What is SLU-PP-332?
Research overview based on the cited scientific literature.
Evidence Status: Preclinical only—no human trials exist[1][11].
Mechanism: Pan-ERR agonist; activates aerobic-exercise gene program and enhances mitochondrial function.
Storage: Lyophilized frozen; reconstituted refrigerated.
Storage Instructions
Proper storage preserves compound stability[7][8][9][10].
Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycles.
Allow vials to reach room temperature before opening to reduce condensation.
Protect from light during storage and handling.
How is SLU-PP-332 studied?
SLU-PP-332 is a synthetic small-molecule pan-agonist of the estrogen-related receptors (ERRα, ERRβ, and ERRγ), with strongest activity at ERRα[1][11]. In murine studies, acute administration activated an aerobic-exercise transcriptional program, increased mitochondrial respiration and fatty-acid oxidation in skeletal muscle, and improved endurance capacity and cardiometabolic phenotypes[3]. The compound acts as an “exercise mimetic” by engaging metabolic pathways typically activated during physical training, without requiring the mechanical stress of actual exercise. However, all evidence to date is preclinical—no human trials have been conducted.
What does the research report about SLU-PP-332?
Preclinical Observations
Findings from murine studies only.
Metabolic effects: Enhanced mitochondrial function, increased fatty-acid oxidation, improved glucose tolerance in diet-induced obese mice[2].
Cardiac benefits: Ameliorated heart failure through enhanced cardiac fatty-acid metabolism and mitochondrial function in preclinical models[3].
Endurance enhancement: Increased treadmill running capacity and muscle oxidative capacity in mice[1].
Renal effects: Reversed mitochondrial dysfunction and inflammation in aging kidney models[4].
Human safety unknown: No data on human tolerability, pharmacokinetics, or adverse effects exist.
Route / Formulation-Specific Research
Published murine studies used intraperitoneal administration twice daily (25–50 mg/kg)[1][2][3]. Daily mcg values in the protocol are expressed for a 25 g mouse. No reputable sources support once-daily subcutaneous use for this compound.
Research Limitations / Risk Notes
PRECLINICAL RESEARCH COMPOUND: PRECLINICAL RESEARCH COMPOUND: SLU-PP-332 is a synthetic pan-agonist of estrogen-related receptors (ERRα/β/γ) studied exclusively in murine models for its ability to activate an aerobic-exercise gene program, enhance mitochondrial function, and improve endurance and cardiometabolic phenotypes[1][2][3]. No human trials have been conducted as of November 2025. This educational protocol reflects published murine regimens using intraperitoneal administration.
Research Considerations
Contextual factors for preclinical research.
SLU-PP-332 was studied alongside exercise training in some murine models, suggesting potential synergistic effects.
Diet composition (standard chow vs. high-fat diet) influenced metabolic outcomes in published studies.
Environmental controls (temperature, housing conditions) should be standardized in research protocols.
Compound stability and handling procedures are critical for reproducible results.
Important Note
This content is provided for scientific research and educational purposes only. It does not provide medical advice, diagnosis, treatment, dosing, or administration instructions. The compounds discussed may be investigational and are not presented as approved for human use.
